Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome

Next Previous
Trial Profile

A Phase 1/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of BCX17725 in Healthy Participants and Multiple Doses of BCX17725 in Participants With Netherton Syndrome

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BCX 17725 (Primary)
  • Indications Netherton Syndrome
  • Focus Adverse reactions; First in man
  • Sponsors BioCryst Pharmaceuticals

Most Recent Events

  • 05 May 2025 According to a BioCryst Pharmaceuticals media release, the FDA has cleared the investigational new drug application (IND) which will enable its clinical trial of BCX17725 for the treatment of Netherton syndrome, to enroll patients in the United States. This phase 1 trial is also open in Australia. The company expects initial data from the program in 2025.
  • 10 Jan 2025 According to a BioCryst Pharmaceuticals media release, operating expenses are forecasted at between $425 million and $435 million for the year includes additional commercial investment to support various activities including RnD investments in clinical activities for both BCX17725 and avoralstat.
  • 02 Oct 2024 According to BioCryst Pharmaceuticals media release, company expects to report initial results from the trial by the end of 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top